A Phase 2/3 interventional study of Bictegravir and Lenacapavir in HIV-1-infection, sponsored by Gilead Sciences. Active, not recruiting at 94 sites in 15 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-05.
Sponsored by Gilead Sciences · Phase 2/3, Interventional, and Treatment
Ph2 PK data was included as part of the 2024 HIV-G presentation: https://hivglasgow.org/wp-content/uploads/2025/02/P049_Arora.pdf
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The goal of this clinical study is to learn more about the effects of switching to the study drugs, bictegravir (BIC) plus lenacapavir (LEN), versus current therapy (Phase 2) and BIC/LEN fixed-dose combination (FDC) versus current therapy (Phase 3) in people living with HIV (PWH).
Gilead Sciences is the lead sponsor of 692 studies on the registry; 26 are open to participants now.
Of its 261 completed or terminated interventional studies of FDA-regulated products, 251 (96%) have results posted.
Counted across the registry records on this site, refreshed daily.
Key Inclusion Criteria:
Currently receiving a complex antiretroviral (ARV) regimen due to previous viral resistance, or intolerance, or to existing single-tablet regimens (STR), and on this regimen for at least 6 months prior to the screening visit. The criteria to define a complex regimen in this study are as follows:
Key Exclusion Criteria:
Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will switch from their Stable Baseline Regimen (SBR) to a regimen of BIC 75 mg + LEN 25 mg, tablets administered orally once daily for up to 24 weeks. Participants will receive a 2-day pharmacokinetic (PK) oral loading dose of LEN 600 mg, on Days 1 and 2, in addition to the daily doses of BIC 75 mg + LEN 25 mg starting on Day 1. Participants who discontinue early or complete the Randomized Phase (RP) will have an option to continue in Extension Period (EP)
Drug: Bictegravir · Drug: Lenacapavir
Participants will switch from their SBR to a regimen of BIC 75 mg + LEN 50 mg, tablets administered orally once daily for up to 24 weeks. Participants will receive a 2-day PK oral loading dose of LEN 600 mg, on Days 1 and 2, in addition to the daily doses of BIC 75 mg + LEN 50 mg starting on Day 1. Participants who discontinue early or complete the RP will have an option to continue in EP.
Drug: Bictegravir · Drug: Lenacapavir
Participants will continue with their SBR for up to 24 weeks. Participants who discontinue early or complete the RP will have an option to continue in EP.
Drug: Stable Baseline Regimen
Participants will switch from their SBR to a regimen of BIC/LEN 75mg/50mg FDC, administered orally once daily for up to 48 weeks. Participants will receive a 2-day PK oral loading dose of LEN 600 mg, on Days 1 and 2, in addition to the daily doses of BIC/LEN 75 mg/50 mg FDC starting on Day 1. Participants who discontinue early or complete the RP will have an option to continue in EP.
Drug: BIC/LEN FDC
Participants will continue with their SBR for up to 48 weeks. Participants who will discontinue early or complete the RP had an option to continue in EP.
Drug: Stable Baseline Regimen
At the end of randomized treatment, participants in Phase 2 and Phase 3 treatment groups who discontinue early or complete the RP will be given an option to enter in EP and will receive BIC/LEN 75/50 mg FDC until the drug is available in market or Gilead elects to withdraw the study. Participants in the SBR groups (Phase 2 Treatment Group 3 and Phase 3 Treatment Group 2 will also receive a 2-day PK oral loading dose of LEN 600 mg, on Days 1 and 2 of EP).
Drug: Lenacapavir · Drug: BIC/LEN FDC
Tablets administered orally without regard to food
Also known as: GS-9883
Tablets administered orally without regard to food
Also known as: GS-6207
Drug page: Bictegravir
Tablets administered orally without regard to food
Also known as: Bixlenvo™
SBR will include a combination of antiretroviral (ARV) regimen. ARV regimen may include the following, except for participants taking a single tablet regimen or taking a complete parenteral regimen (Cabenuva). * Nucleos(t)ide Reverse Transcriptase Inhibitors: * Abacavir * Emtricitabine * Lamivudine * Tenofovir alafenamide * Tenofovir disoproxil fumarate * Zidovudine * Non-Nucleosite Reverse Transcriptase Inhibitors: * Delavirdine * Efavirenz * Nevirapine * Rilpivirine * Doravirine * Integrase Inhibitors: * Bictegravir * Cabotegravir * Dolutegravir * Elvitegravir * Raltegravir * Protease Inhibitors: * Atazanavir * Darunavir * Fosamprenavir * Indinavir * Lopinavir * Nelfinavir * Saquinavir * Tipranavir * Chemokine Co-receptor 5 (CCR5) Antagonist: * Maraviroc * Fusion Inhibitors: * Enfuvirtide * gp120 Attachment Inhibitor: * Fostemsavir * Anti-CD4 Monoclonal Antibodies: * Ibalizumab-uiyk
Phase 2: Percentage of Participants With Human Immunodeficiency Virus-1 Ribonucleic Acid (HIV-1 RNA) ≥ 50 Copies/mL at Week 24 as Determined by the United States Food and Drug Administration (US FDA) Defined Snapshot Algorithm
Participants who had the last available on-treatment HIV-1 RNA≥ 50 copies/mL in the week 24 analysis window, or who did not have on-treatment HIV-1 RNA data in the week 24 analysis window and participants who discontinued study drug prior to or in the week 24 analysis window due to lack of efficacy, or who discontinued study drug prior to or in the week 24 analysis window due to adverse event (AE) or death and have the last available on-treatment HIV-1 RNA≥ 50 copies/mL, or who discontinued study drug prior to or in the week 24 analysis window due to reasons other than AE, death, or lack of efficacy and have the last available on-treatment HIV-1 RNA ≥ 50 copies/mL were included. The Week 24 window for snapshot algorithm was between Days 127 and 210 (inclusively). Percentages were rounded off.
Time frame: Week 24
Phase 3: Percentages of Participants With HIV-1 RNA ≥ 50 Copies/mL at Week 48 as Determined by the US FDA-defined Snapshot Algorithm
Participants who had the last available on-treatment HIV-1 RNA ≥ 50 copies/mL in the Week 48 analysis window, or who did not have on-treatment HIV-1 RNA data in the Week 48 analysis window and who discontinued study drug prior to or in the Week 48 analysis window due to lack of efficacy, or who discontinued study drug prior to or in the Week 48 analysis window due to AE or death and have the last available on-treatment HIV-1 RNA ≥ 50 copies/mL, or who discontinued study drug prior to or in the Week 48 analysis window due to reasons other than AE, death, or lack of efficacy and have the last available on-treatment HIV-1 RNA ≥ 50 copies/mL were included. The Week 48 window for snapshot algorithm was between Days 295 and 378 (inclusively). Percentages were rounded off.
Time frame: Week 48
Phase 2: Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 24 as Determined by the US FDA-defined Snapshot Algorithm
Participants who had the last available on-treatment HIV-1 RNA \< 50 copies/mL in the Week 24 analysis window were included. The Week 24 window for snapshot algorithm was between Days 127 and 210 (inclusively). Percentages were rounded off.
Time frame: Week 24
Phase 2: Change From Baseline in Clusters of Differentiation 4 (CD4) Cell Count at Week 24
Time frame: Baseline, Week 24
Phase 2: Percentage of Participants Experiencing Treatment-Emergent Adverse Events (TEAEs) Through Week 24
An adverse event (AE) was any untoward medical occurrence in a clinical study participant administered a study drug that did not necessarily had a causal relationship with the treatment. TEAEs were defined as any AE that begins on or after the date of first dose of study drug up to the date of last dose of study drug plus 60 days (for BIC+LEN or BIC/LEN FDC) or 30 days (for SBR) or any AE leading to study drug discontinuation. Percentages were rounded off.
Time frame: First dose date up to Week 24
Phase 2: PK Parameter: Cmax for Bictegravir (BIC) at Steady State
Cmax is defined as the maximum observed concentration of drug. Participants chose to participate at either Week 16 or Week 24 visit as the steady state visit.
Time frame: At Week 16 or 24
Phase 2: PK Parameter: Cmax for Lenacapavir (LEN) at Steady State
Cmax is defined as the maximum observed concentration of drug. Participants chose to participate at either Week 16 or Week 24 visit as the steady state visit.
Time frame: At Week 16 or Week 24
Phase 2: PK Parameter: AUCtau of BIC at Steady State
AUCtau is defined as the area under the concentration versus time curve over the dosing interval. Participants chose to participate at either Week 16 or Week 24 visit as the steady state visit.
Time frame: At Week 16 or 24
Phase 2: PK Parameter: AUCtau for LEN at Steady State
AUCtau is defined as the area under the concentration versus time curve over the dosing interval. Participants chose to participate at either Week 16 or Week 24 visit as the steady state visit.
Time frame: At Week 16 or Week 24
Phase 2: PK Parameter: Ctrough of BIC at Steady State
Ctrough is defined as the observed drug concentration at the end of the dosing interval. Participants chose to participate at either Week 16 or Week 24 visit as the steady state visit.
Time frame: At Week 16 or Week 24
Phase 2: PK Parameter: Ctrough of LEN at Steady State
Ctrough is defined as the observed drug concentration at the end of the dosing interval. Participants chose to participate at either Week 16 or Week 24 visit as the steady state visit.
Time frame: At Week 16 or Week 24
Phase 3: Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 48 as Determined by the US FDA-defined Snapshot Algorithm
Participants who had the last available on-treatment HIV-1 RNA \< 50 copies/mL in the Week 48 analysis window were included. The Week 48 window for snapshot algorithm was between Days 295 and 378 (inclusively).
Time frame: Week 48
Phase 3: Change From Baseline in CD4 Cell Count at Week 48
An AE was any untoward medical occurrence in a clinical study participant administered a study drug that did not necessarily had a causal relationship with the treatment. TEAEs were defined as any AE that begins on or after the date of first dose of study drug up to the date of last dose of study drug plus 60 days (for BIC+LEN or BIC/LEN FDC) or 30 days (for SBR) or any AE leading to study drug discontinuation. Percentages were rounded off.
Time frame: Baseline, Week 48
Phase 3: Percentage of Participants Experiencing TEAEs Through Week 48
An AE was any untoward medical occurrence in a clinical study participant administered a study drug that did not necessarily had a causal relationship with the treatment. TEAEs were defined as 1 or both of the following: Any AEs leading to premature discontinuation of study drug, or any AEs with an onset date on or after the study drug start date and no later than the last exposure date after permanent discontinuation of the study drug. Percentages were rounded off.
Time frame: First dose date up to Week 48
Phase 3 Treatment Group 1: (BIC/LEN 75 mg/50 mg FDC): Percentage of Participants With HIV-1 RNA ≥ 50 Copies/mL at Week 96 as Determined by the US FDA-defined Snapshot Algorithm
Time frame: Week 96
Phase 3 Treatment Group 1: (BIC/LEN 75 mg/50 mg FDC): Percentage of Participants With HIV-1 RNA ≥ 50 Copies/mL at Week 144 as Determined by the US FDA-defined Snapshot Algorithm
Time frame: Week 144
Phase 3 Treatment Group 1: (BIC/LEN 75 mg/50 mg FDC): Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 96 as Determined by the US FDA-defined Snapshot Algorithm
Time frame: Week 96
Phase 3 Treatment Group 1: (BIC/LEN 75 mg/50 mg FDC): Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 144 as Determined by the US FDA-defined Snapshot Algorithm
Time frame: Week 144
Phase 3 Treatment Group 1: (BIC/LEN 75 mg/50 mg FDC): Change From Baseline in CD4 Cell Count at Week 96
Time frame: Baseline, Week 96
Phase 3 Treatment Group 1: (BIC/LEN 75 mg/50 mg FDC): Change From Baseline in CD4 Cell Count at Week 144
Time frame: Baseline, Week 144
Phase 3 Treatment Group 1: (BIC/LEN 75 mg/50 mg FDC): Percentage of Participants Experiencing TEAEs Through Week 96
Time frame: Week 96
Phase 3 Treatment Group 1: (BIC/LEN 75 mg/50 mg FDC): Percentage of Participants Experiencing TEAEs Through Week 144
Time frame: Week 144
Participants were enrolled at study sites in South America, Oceania, North America, Europe, Asia and Africa.
| Milestone | Phase 2: Treatment Group 1: BIC 75 mg + LEN 25 mg | Phase 2: Treatment Group 2: BIC 75 mg + LEN 50 mg | Phase 2: Treatment Group 3: SBR | Phase 3: Treatment Group 1: BIC/LEN 75 mg/50 mg FDC | Phase 3: Treatment Group 2: SBR |
|---|---|---|---|---|---|
| Started | 51 | 52 | 25 | 373 | 188 |
| Completed | 0 | 0 | 0 | 0 | 0 |
| Not completed | 51 | 52 | 25 | 373 | 188 |
| Withdrew: Still on study | 49 | 49 | 25 | 358 | 177 |
| Withdrew: Adverse event | 1 | 1 | 0 | 6 | 1 |
| Withdrew: Withdrew consent | 1 | 1 | 0 | 2 | 3 |
| Withdrew: Death | 0 | 1 | 0 | 5 | 0 |
| Withdrew: Randomized but never treated | 0 | 0 | 0 | 2 | 2 |
| Withdrew: Investigator's discretion | 0 | 0 | 0 | 0 | 3 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 2 |
Participants who had the last available on-treatment HIV-1 RNA≥ 50 copies/mL in the week 24 analysis window, or who did not have on-treatment HIV-1 RNA data in the week 24 analysis window and participants who discontinued study drug prior to or in the week 24 analysis window due to lack of efficacy, or who discontinued study drug prior to or in the week 24 analysis window due to adverse event (AE) or death and have the last available on-treatment HIV-1 RNA≥ 50 copies/mL, or who discontinued study drug prior to or in the week 24 analysis window due to reasons other than AE, death, or lack of efficacy and have the last available on-treatment HIV-1 RNA ≥ 50 copies/mL were included. The Week 24 window for snapshot algorithm was between Days 127 and 210 (inclusively). Percentages were rounded off.
| percentage of participants | Phase 2: Treatment Group 1: BIC 75 mg + LEN 25 mg | Phase 2: Treatment Group 2: BIC 75 mg + LEN 50 mg | Phase 2: Treatment Group 3: SBR |
|---|---|---|---|
| Phase 2: Percentage of Participants With Human Immunodeficiency Virus-1 Ribonucleic Acid (HIV-1 RNA) ≥ 50 Copies/mL at Week 24 as Determined by the United States Food and Drug Administration (US FDA) Defined Snapshot Algorithm | 0 | 1.9 | 0 |
Participants who had the last available on-treatment HIV-1 RNA ≥ 50 copies/mL in the Week 48 analysis window, or who did not have on-treatment HIV-1 RNA data in the Week 48 analysis window and who discontinued study drug prior to or in the Week 48 analysis window due to lack of efficacy, or who discontinued study drug prior to or in the Week 48 analysis window due to AE or death and have the last available on-treatment HIV-1 RNA ≥ 50 copies/mL, or who discontinued study drug prior to or in the Week 48 analysis window due to reasons other than AE, death, or lack of efficacy and have the last available on-treatment HIV-1 RNA ≥ 50 copies/mL were included. The Week 48 window for snapshot algorithm was between Days 295 and 378 (inclusively). Percentages were rounded off.
| percentage of participants | Phase 3:Treatment Group 1:BIC/LEN 75 mg/50 mg FDC | Phase 3: Treatment Group 2: SBR |
|---|---|---|
| Phase 3: Percentages of Participants With HIV-1 RNA ≥ 50 Copies/mL at Week 48 as Determined by the US FDA-defined Snapshot Algorithm | 0.8 | 1.1 |
Participants who had the last available on-treatment HIV-1 RNA \< 50 copies/mL in the Week 24 analysis window were included. The Week 24 window for snapshot algorithm was between Days 127 and 210 (inclusively). Percentages were rounded off.
| percentage of participants | Phase 2: Treatment Group 1: BIC 75 mg + LEN 25 mg | Phase 2: Treatment Group 2: BIC 75 mg + LEN 50 mg | Phase 2: Treatment Group 3: SBR |
|---|---|---|---|
| Phase 2: Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 24 as Determined by the US FDA-defined Snapshot Algorithm | 96.1 | 96.2 | 100 |
| cells/µL | Phase 2: Treatment Group 1: BIC 75 mg + LEN 25 mg | Phase 2: Treatment Group 2: BIC 75 mg + LEN 50 mg | Phase 2: Treatment Group 3: SBR |
|---|---|---|---|
| Baseline | 608 ± 238.9 | 684 ± 329.8 | 566 ± 304.5 |
| Change at Week 24 | 33 ± 155.0 | 5 ± 145.3 | 43 ± 179.6 |
An adverse event (AE) was any untoward medical occurrence in a clinical study participant administered a study drug that did not necessarily had a causal relationship with the treatment. TEAEs were defined as any AE that begins on or after the date of first dose of study drug up to the date of last dose of study drug plus 60 days (for BIC+LEN or BIC/LEN FDC) or 30 days (for SBR) or any AE leading to study drug discontinuation. Percentages were rounded off.
| percentage of participants | Phase 2: Treatment Group 1: BIC 75 mg + LEN 25 mg | Phase 2: Treatment Group 2: BIC 75 mg + LEN 50 mg | Phase 2: Treatment Group 3: SBR |
|---|---|---|---|
| Phase 2: Percentage of Participants Experiencing Treatment-Emergent Adverse Events (TEAEs) Through Week 24 | 76.5 | 63.5 | 68.0 |
Cmax is defined as the maximum observed concentration of drug. Participants chose to participate at either Week 16 or Week 24 visit as the steady state visit.
| ng/mL | Phase 2: Treatment Group 1: BIC 75 mg + LEN 25 mg | Phase 2: Treatment Group 2: BIC 75 mg + LEN 50 mg |
|---|---|---|
| Phase 2: PK Parameter: Cmax for Bictegravir (BIC) at Steady State | 9400 ± 3020 | 9860 ± 3480 |
Cmax is defined as the maximum observed concentration of drug. Participants chose to participate at either Week 16 or Week 24 visit as the steady state visit.
| ng/mL | Phase 2: Treatment Group 1: BIC 75 mg + LEN 25 mg | Phase 2: Treatment Group 2: BIC 75 mg + LEN 50 mg |
|---|---|---|
| Phase 2: PK Parameter: Cmax for Lenacapavir (LEN) at Steady State | 87.4 ± 77.6 | 134 ± 101 |
AUCtau is defined as the area under the concentration versus time curve over the dosing interval. Participants chose to participate at either Week 16 or Week 24 visit as the steady state visit.
| h*ng/mL | Phase 2: Treatment Group 1: BIC 75 mg + LEN 25 mg | Phase 2: Treatment Group 2: BIC 75 mg + LEN 50 mg |
|---|---|---|
| Phase 2: PK Parameter: AUCtau of BIC at Steady State | 143000 ± 48300 | 154000 ± 67000 |
AUCtau is defined as the area under the concentration versus time curve over the dosing interval. Participants chose to participate at either Week 16 or Week 24 visit as the steady state visit.
| h*ng/mL | Phase 2: Treatment Group 1: BIC 75 mg + LEN 25 mg | Phase 2: Treatment Group 2: BIC 75 mg + LEN 50 mg |
|---|---|---|
| Phase 2: PK Parameter: AUCtau for LEN at Steady State | 1530 ± 1100 | 2620 ± 2100 |
Ctrough is defined as the observed drug concentration at the end of the dosing interval. Participants chose to participate at either Week 16 or Week 24 visit as the steady state visit.
| h*ng/mL | Phase 2: Treatment Group 1: BIC 75 mg + LEN 25 mg | Phase 2: Treatment Group 2: BIC 75 mg + LEN 50 mg |
|---|---|---|
| Phase 2: PK Parameter: Ctrough of BIC at Steady State | 4270 ± 1930 | 4800 ± 2950 |
Ctrough is defined as the observed drug concentration at the end of the dosing interval. Participants chose to participate at either Week 16 or Week 24 visit as the steady state visit.
| h*ng/mL | Phase 2: Treatment Group 1: BIC 75 mg + LEN 25 mg | Phase 2: Treatment Group 2: BIC 75 mg + LEN 50 mg |
|---|---|---|
| Phase 2: PK Parameter: Ctrough of LEN at Steady State | 63.4 ± 43.9 | 104 ± 83.7 |
Participants who had the last available on-treatment HIV-1 RNA \< 50 copies/mL in the Week 48 analysis window were included. The Week 48 window for snapshot algorithm was between Days 295 and 378 (inclusively).
| percentage of participants | Phase 3: Treatment Group 1: BIC/LEN 75 mg/50 mg FDC | Phase 3: Treatment Group 2: SBR |
|---|---|---|
| Phase 3: Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 48 as Determined by the US FDA-defined Snapshot Algorithm | 96.0 | 93.5 |
An AE was any untoward medical occurrence in a clinical study participant administered a study drug that did not necessarily had a causal relationship with the treatment. TEAEs were defined as any AE that begins on or after the date of first dose of study drug up to the date of last dose of study drug plus 60 days (for BIC+LEN or BIC/LEN FDC) or 30 days (for SBR) or any AE leading to study drug discontinuation. Percentages were rounded off.
| cells/µL | Phase 3: Treatment Group 1: BIC/LEN 75 mg/50 mg FDC | Phase 3: Treatment Group 2: SBR |
|---|---|---|
| Baseline | 665 ± 296.2 | 629 ± 274.7 |
| Change at Week 48 | 18 ± 176.3 | 6 ± 166.8 |
An AE was any untoward medical occurrence in a clinical study participant administered a study drug that did not necessarily had a causal relationship with the treatment. TEAEs were defined as 1 or both of the following: Any AEs leading to premature discontinuation of study drug, or any AEs with an onset date on or after the study drug start date and no later than the last exposure date after permanent discontinuation of the study drug. Percentages were rounded off.
| percentage of participants | Phase 3: Treatment Group 1: BIC/LEN 75 mg/50 mg FDC | Phase 3: Treatment Group 2: SBR |
|---|---|---|
| Phase 3: Percentage of Participants Experiencing TEAEs Through Week 48 | 79.5 | 81.2 |
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Collected over All-Cause Mortality and Adverse Events: Up to 48 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Phase 2: Treatment Group 1: BIC 75 mg + LEN 25 mg | 0/51 (0%) | 3/51 (5.9%) | 20/51 (39.2%) |
| Phase 2: Treatment Group 2: BIC 75 mg + LEN 50 mg | 1/52 (1.9%) | 2/52 (3.8%) | 13/52 (25%) |
| Phase 2: Treatment Group 3: SBR | 0/25 (0%) | 2/25 (8%) | 5/25 (20%) |
| Phase 3: Treatment Group 1: BIC/ LEN 75 mg/50 mg FDC | 5/373 (1.3%) | 52/371 (14%) | 141/371 (38%) |
| Phase 3: Treatment Group 2: SBR | 0/188 (0%) | 22/186 (11.8%) | 70/186 (37.6%) |
| Event | Phase 2: Treatment Group 1: BIC 75 mg + LEN 25 mg | Phase 2: Treatment Group 2: BIC 75 mg + LEN 50 mg | Phase 2: Treatment Group 3: SBR | Phase 3: Treatment Group 1: BIC/ LEN 75 mg/50 mg FDC | Phase 3: Treatment Group 2: SBR |
|---|---|---|---|---|---|
| Cardiac failure acuteCardiac disorders | 0/51 | 0/52 | 1/25 | 0/371 | 0/186 |
| CardiomyopathyCardiac disorders | 0/51 | 0/52 | 1/25 | 0/371 | 0/186 |
| Intracardiac thrombusCardiac disorders | 0/51 | 0/52 | 1/25 | 0/371 | 0/186 |
| CellulitisInfections and infestations | 0/51 | 0/52 | 1/25 | 1/371 | 0/186 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 0/51 | 0/52 | 1/25 | 1/371 | 1/186 |
| ThrombophlebitisVascular disorders | 0/51 | 0/52 | 1/25 | 0/371 | 0/186 |
| GastroenteritisInfections and infestations | 1/51 | 0/52 | 0/25 | 0/371 | 0/186 |
| Muscular weaknessMusculoskeletal and connective tissue disorders | 1/51 | 0/52 | 0/25 | 0/371 | 0/186 |
| Balance disorderNervous system disorders | 1/51 | 0/52 | 0/25 | 0/371 | 0/186 |
| AnxietyPsychiatric disorders | 1/51 | 0/52 | 0/25 | 0/371 | 0/186 |
| Event | Phase 2: Treatment Group 1: BIC 75 mg + LEN 25 mg | Phase 2: Treatment Group 2: BIC 75 mg + LEN 50 mg | Phase 2: Treatment Group 3: SBR | Phase 3: Treatment Group 1: BIC/ LEN 75 mg/50 mg FDC | Phase 3: Treatment Group 2: SBR |
|---|---|---|---|---|---|
| Upper respiratory tract infectionInfections and infestations | 2/51 | 2/52 | 1/25 | 34/371 | 24/186 |
| DiarrhoeaGastrointestinal disorders | 5/51 | 2/52 | 1/25 | 22/371 | 11/186 |
| NasopharyngitisInfections and infestations | 4/51 | 0/52 | 0/25 | 26/371 | 17/186 |
| Covid-19Infections and infestations | 4/51 | 2/52 | 2/25 | 18/371 | 6/186 |
| HypertensionVascular disorders | 1/51 | 4/52 | 1/25 | 20/371 | 6/186 |
| HeadacheNervous system disorders | 2/51 | 2/52 | 0/25 | 28/371 | 4/186 |
| CoughRespiratory, thoracic and mediastinal disorders | 3/51 | 1/52 | 0/25 | 18/371 | 11/186 |
| ConstipationGastrointestinal disorders | 3/51 | 2/52 | 0/25 | 11/371 | 5/186 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 3/51 | 1/52 | 0/25 | 19/371 | 8/186 |
The Safety Analysis Set included all participants who took at least 1 dose of any study drug in Treatment Groups 1 and 2 in Phase 2 , or Treatment Group 1 in Phase 3, or continued with their SBR in Treatment Group 3 in Phase 2 and Treatment Group 2 in Phase 3.
| Age, Categorical(Participants) | Phase 2: Treatment Group 1: BIC 75 mg + LEN 25 mg | Phase 2: Treatment Group 2: BIC 75 mg + LEN 50 mg | Phase 2: Treatment Group 3: SBR | Phase 3: Treatment Group 1: BIC/LEN 75 mg/50 mg FDC | Phase 3: Treatment Group 2: SBR | Total |
|---|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 33 | 38 | 20 | 256 | 127 | 474 |
| >=65 years | 18 | 14 | 5 | 115 | 59 | 211 |
| Age, Continuous(years) | Phase 2: Treatment Group 1: BIC 75 mg + LEN 25 mg | Phase 2: Treatment Group 2: BIC 75 mg + LEN 50 mg | Phase 2: Treatment Group 3: SBR | Phase 3: Treatment Group 1: BIC/LEN 75 mg/50 mg FDC | Phase 3: Treatment Group 2: SBR | Total |
|---|---|---|---|---|---|---|
| Mean | 61 ± 9.3 | 60 ± 8.9 | 58 ± 6.9 | 60 ± 9.3 | 59 ± 10.2 | 60 ± 9.4 |
| Sex: Female, Male(Participants) | Phase 2: Treatment Group 1: BIC 75 mg + LEN 25 mg | Phase 2: Treatment Group 2: BIC 75 mg + LEN 50 mg | Phase 2: Treatment Group 3: SBR | Phase 3: Treatment Group 1: BIC/LEN 75 mg/50 mg FDC | Phase 3: Treatment Group 2: SBR | Total |
|---|---|---|---|---|---|---|
| Female | 13 | 7 | 4 | 64 | 36 | 124 |
| Male | 38 | 45 | 21 | 307 | 150 | 561 |
| Race/Ethnicity, Customized(Participants) | Phase 2: Treatment Group 1: BIC 75 mg + LEN 25 mg | Phase 2: Treatment Group 2: BIC 75 mg + LEN 50 mg | Phase 2: Treatment Group 3: SBR | Phase 3: Treatment Group 1: BIC/LEN 75 mg/50 mg FDC | Phase 3: Treatment Group 2: SBR | Total |
|---|---|---|---|---|---|---|
| White | 29 | 34 | 20 | 260 | 124 | 467 |
| Black or African American | 18 | 16 | 5 | 64 | 33 | 136 |
| Not Collected | 0 | 0 | 0 | 19 | 17 | 36 |
| Asian | 2 | 2 | 0 | 16 | 9 | 29 |
| Other or More Than One Race | 2 | 0 | 0 | 10 | 2 | 14 |
| American Indian or Alaska Native | 0 | 0 | 0 | 1 | 1 | 2 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 1 | 0 | 1 |
| Race/Ethnicity, Customized(Participants) | Phase 2: Treatment Group 1: BIC 75 mg + LEN 25 mg | Phase 2: Treatment Group 2: BIC 75 mg + LEN 50 mg | Phase 2: Treatment Group 3: SBR | Phase 3: Treatment Group 1: BIC/LEN 75 mg/50 mg FDC | Phase 3: Treatment Group 2: SBR | Total |
|---|---|---|---|---|---|---|
| Not Hispanic or Latino | 43 | 42 | 21 | 270 | 128 | 504 |
| Hispanic or Latino | 7 | 9 | 4 | 80 | 42 | 142 |
| Not Collected | 1 | 1 | 0 | 21 | 16 | 39 |
| Region of Enrollment(Participants) | Phase 2: Treatment Group 1: BIC 75 mg + LEN 25 mg | Phase 2: Treatment Group 2: BIC 75 mg + LEN 50 mg | Phase 2: Treatment Group 3: SBR | Phase 3: Treatment Group 1: BIC/LEN 75 mg/50 mg FDC | Phase 3: Treatment Group 2: SBR | Total |
|---|---|---|---|---|---|---|
| United States | 41 | 38 | 19 | 134 | 70 | 302 |
| Canada | 7 | 9 | 4 | 42 | 19 | 81 |
| Germany | 0 | 0 | 0 | 35 | 12 | 47 |
| Argentina | 0 | 0 | 0 | 31 | 13 | 44 |
| Australia | 2 | 2 | 1 | 25 | 12 | 42 |
| Spain | 0 | 0 | 0 | 25 | 14 | 39 |
| Italy | 0 | 0 | 0 | 25 | 11 | 36 |
| France | 0 | 0 | 0 | 18 | 16 | 34 |
| United Kingdom | 0 | 0 | 0 | 19 | 9 | 28 |
| Taiwan | 0 | 0 | 0 | 5 | 4 | 9 |
| South Africa | 0 | 0 | 0 | 4 | 2 | 6 |
| Dominican Republic | 0 | 2 | 1 | 1 | 1 | 5 |
| Puerto Rico | 1 | 1 | 0 | 2 | 1 | 5 |
| South Korea | 0 | 0 | 0 | 3 | 1 | 4 |
| Japan | 0 | 0 | 0 | 2 | 1 | 3 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Aug 2022 to primary completion in Sep 2025, 37 months.
Results were first posted in Oct 2026, 1 year after primary completion.
Completion moved once since we started tracking on Sep 25, 2026: Jul 2028 → Dec 2029, on Oct 21, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
Ph2 PK data was included as part of the 2024 HIV-G presentation: https://hivglasgow.org/wp-content/uploads/2025/02/P049_Arora.pdf
Ph2 PK data was included as part of the 2024 HIV-G presentation: https://hivglasgow.org/wp-content/uploads/2025/02/P049_Arora.pdf
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Bictegravir · Lenacapavir